Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS) Translational Study

Prostate Cancer Clinical Trial

— RADICALS-TR  

Official title:

A Translational Study of Samples From the Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS) Prostate Cancer Trial to Identify Those Most Likely to Benefit From Androgen Deprivation With Salvage Radiotherapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06145958
• Other study ID #: 159874
• Secondary ID: 329626
• Status: Not yet recruiting
• Start date: January 1, 2024
• Est. completion date: August 30, 2028

Study information

• Verified date: November 2023
• Source: University College, London
• Contact: Matthew W Fittall, BMBCh PhD
• Phone: 020 7679 6500
• Email: Matthew.Fittall[@]ucl.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this translational study is to test the use of biomarkers in salvage treatment for prostate cancer after a previous operation to remove the prostate. The main question it aims to answer is: • Can a biomarker identify a group of patients most likely to benefit from androgen deprivation therapy in conjunction with salvage radiotherapy No new participants will be involved, but tumour samples will be acquired, for patients that gave their permission in the completed RADICALS RT and HD studies.

Description:

Early prostate cancer represents a wide spectrum of disease. Indolent disease is unlikely to ever become symptomatic and treatment is needlessly morbid and costly. Aggressive disease warrants intensification of therapy. Current clinical methods are poor at discriminating these outcomes. The RADICALS trial was the largest trial conducted to date in men requiring further curative treatment after an operation. It already defined the role for radiotherapy after surgery (prostatectomy). The standard of care is now for blood test (PSA) monitoring after prostatectomy with radiotherapy offered when the PSA rises. The role and duration of hormone treatment (androgen deprivation), given in combination with radiotherapy, remains less clear. Currently if androgen deprivation is to be given, the RADICALS data support the use of a 24-month course, but this entails a considerable burden of side-effects for patients. Pathological and biological markers are needed to identify those most likely to benefit from androgen deprivation. In RADICALS-TR, the investigators will conduct translational analyses on the biopsy and prostatectomy specimens from the RADICALS trial. The investigators aim to identify prognostic features and biomarkers predictive of benefit from androgen therapy. The investigators will prioritise the refinement and validation of clinical biomarkers already close to clinical utilisation. In this way it is hoped that findings can rapidly translate to stratified clinical trials and improved patient care.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 2585
• Est. completion date: August 30, 2028
• Est. primary completion date: August 30, 2028
• Gender: Male
• Age group: 18 Years to 99 Years

Eligibility

DISEASE CHARACTERISTICS:

Inclusion criteria:

Diagnosis of nonmetastatic adenocarcinoma of the prostate Must have undergone radical prostatectomy Post-operative serum prostate-specific antigen (PSA) < 0.4 ng/mL No post-operative biochemical failure, defined as EITHER two consecutive rises in PSA and final PSA > 0.1 ng/mL OR three consecutive rises in PSA (for patients undergoing hormone therapy duration randomization) Exclusion criteria: Known distant metastases from prostate cancer PSA > 5 ng/mL at the time of hormone randomization (for patients undergoing hormone therapy duration randomization)

PATIENT CHARACTERISTICS:

• No other active malignancy likely to interfere with protocol treatment or follow-up.
• Consent has been given within the RADICALS (RT/HD) trial to translational research and follow up. PRIOR CONCURRENT THERAPY: Inclusion criteria: See Disease Characteristics Co-enrollment to other trials is permitted, providing this does not interfere with the outcome measures 5-a reductase inhibitors, soya, selenium, and vitamin E are acceptable non-trial therapies Exclusion criteria: Prior hormone therapy Bilateral orchidectomy Prior pelvic radiotherapy Neoadjuvant treatment Other concurrent therapies for prostate cancer (e.g., estrogens or cytotoxic chemotherapy) prior to disease progression

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Luteinising Hormone-Releasing Factor Analogue
Androgen Deprivation Therapy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University College, London

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Freedom from Distant Metastases	The absence of prostate cancer metastases	Up to 12 years
Secondary	Overall survival	Freedom from death from any cause	Up to 12 years
Secondary	Disease Specific Survival	Freedom from prostate cancer specific death	Up to 12 years
Secondary	Freedom from treatment failure	Freedom from PSA progression whilst receiving androgen deprivation therapy	Up to 12 years
Secondary	Clinical Progression Free survival	Clinical progression of prostate cancer or initiation of non-protocol hormone therapy or death from prostate cancer.	Up to 12 years
Secondary	Non protocol hormone therapy	Initiation of hormone therapy other than that randomised.	Up to 12 years
Secondary	Freedom from biochemical progression	Where a biochemical progression event is defined as a PSA level of =0.4ng/ml following radiotherapy or a PSA level of > 2.0ng/ml regardless of prior radiotherapy.	Up to 12 years